Tetraphase Pharmaceuticals to Present at the Annual UBS Global Healthcare Conference
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that Tetraphase Senior Vice President & Chief Financial Officer David Lubner will present at the annual UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 AM a.m. Eastern Time. The conference will take place at The Sheraton Hotel in New York City.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase’s lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.